AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10637064
Drug: Intravenous cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cisplatin (50 mg/m²) plus intravenous epidoxorubicin (60 mg/m²) and intravenous cyclophosphamide (600 mg/m²)
Trial: 8892457
Drug: CY/TBI (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CY/TBI (120 mg/kg cyclophosphamide and 1320 cGy total body irradiation)
Trial: 8892457
Drug: BU/CY (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BU/CY (16 mg/kg Busulfan and 200 mg/kg cyclophosphamide)
Trial: 6607245
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose CMFVP
Trial: 6607245
Drug: Three drug
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three drug combination CAF (doxorubicin)
Trial: 6607245
Drug: CAMELEON (sequentially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAMELEON (sequentially alternating therapy) added to CAF
Trial: 6607245
Drug: Aggressive combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive combination chemotherapeutic approaches
Trial: 11275859
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care and ibuprofen
Trial: 9113182
Drug: esmolol 1
RxNorm normalized name: esmolol 10 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: esmolol 1 mg.kg‐1 + 200 micrograms.kg‐1.min‐1
Trial: 2660557
Drug: Sucralfate 1
RxNorm normalized name: sucralfate 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 1 g three times a day
Trial: 7816004
Drug: Orange juice
RxNorm normalized name: Orange juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange juice only (without K- and Mg-phosphate supplementation)
Trial: 7816004
Drug: Orange juice
RxNorm normalized name: Orange juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange juice with K- and Mg-phosphate supplementation
Trial: 28240625
Drug: In SHAPE
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In SHAPE program (gym membership, weekly individual meetings with a fitness trainer, instruction on healthy eating and nutrition)
Trial: 25648347
Drug: FMI tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMI tablet (500 mg)
Trial: 25648347
Drug: HF meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HF meal (with FMI tablet 300 mg)
Trial: 25648347
Drug: LF meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LF meal (with FMI tablet 300 mg)
Trial: 25648347
Drug: NM (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NM (with FMI tablet 300 mg)
Trial: 24463669
Drug: Nitrofurantoin 100
RxNorm normalized name: nitrofurantoin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin 100 mg once daily during catheterization
Trial: 19620077
Drug: Hypofractionated radiotherapy
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated radiotherapy at 3.0 Gy/fraction (30 Gy total) combined with weekly docetaxel at 60 mg for 2 weeks
Trial: 11474385
Drug: Routine sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine sedation with midazolam (0.07 mg/kg) and meperidine (0.77 mg/kg)
Trial: 3291895
Drug: nifedipine 30
RxNorm normalized name: nifedipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine 30 mg po
Trial: 31538488
Drug: Peer support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer support intervention (6-weekly visits from a peer support worker in addition to routine care)
Trial: 26482148
Drug: Cherry juice
RxNorm normalized name: Cherry Juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cherry juice (200 ml/day)
Trial: 22290680
Drug: iv lornoxicam
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv lornoxicam (8 mg)
Trial: 22290680
Drug: iv paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv paracetamol (1 g)
Trial: 22290680
Drug: iv saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv saline solution (Control)
Trial: 10980880
Drug: Systemic anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic anticoagulation therapy
Trial: 3967455
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg amantadine)
Trial: 3967455
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg amantadine
Trial: 3967455
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg amantadine
Trial: 29588170
Drug: Lira‐basal (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lira‐basal (0.9 mg/day liraglutide plus basal insulin)
Trial: 29588170
Drug: BBIT (basal-bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBIT (basal-bolus insulin therapy)
Trial: 28472303
Drug: Whole Body
RxNorm normalized name: MaxiVision Whole Body Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole Body Vibration (WBV) training (3 × 3 minutes twice daily for 5 months)
Trial: 25445405
Drug: Tripterygium wilfordii
RxNorm normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripterygium wilfordii Hook. f. (TwHF) 1.5 mg/kg/day
Trial: 25445405
Drug: Azathioprine 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine 2.0 mg/kg/day
Trial: 14696664
Drug: Implant-retained overdenture
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implant-retained overdenture (IRO)
Trial: 14696664
Drug: Endosseous implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endosseous implants
Trial: 8697067
Drug: Orlistat 10
RxNorm normalized name: orlistat 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 10 mg, 60 mg, and 120 mg three times a day
Trial: 1781526
Drug: Adrenaline 1:200,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline 1:200,000 administered 5 minutes before 20 ml bupivacaine 0.5%
Trial: 1781526
Drug: Saline followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline followed by 20 ml bupivacaine 0.5% with 100 micrograms adrenaline
Trial: 1781526
Drug: Saline followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline followed by 20 ml plain bupivacaine 0.5%
Trial: 7014790
Drug: Steroid group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid group (5 mg/kg/day of methylprednisolone)
Trial: 7014790
Drug: Nonsteroid group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroid group (no drug)
Trial: 30304936
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (comprehensive discharge planning, offering substance abuse treatment, provision of information on self-scheduling appointments).
Trial: 25503600
Drug: Buprenorphine transdermal
RxNorm normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal system (BTDS) 5, 10, and 20 μg/h (maximum dosage of 20 μg/h)
Trial: 25503600
Drug: Sustained-release tramadol
RxNorm normalized name: tramadol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release tramadol tablets 100 mg (maximum dosage of 400 mg/d)
Trial: 23792641
Drug: PF-3512676 (0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-3512676 (0.20 mg/kg injected subcutaneously once weekly) plus erlotinib (150 mg daily)
Trial: 23792641
Drug: erlotinib alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: erlotinib alone (150 mg daily)
Trial: 19762706
Drug: Conventional, stepwise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional, stepwise fever management with anti‐inflammatory drugs and surface cooling
Trial: 15204145
Drug: Calcipotriol 50
RxNorm normalized name: Calcipotriol 50 microgram/g cutaneous cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol 50 microg/g ointment twice daily for 12 weeks
Trial: 15204145
Drug: Betamethasone 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone 0.1% ointment twice daily for 12 weeks
Trial: 9648983
Drug: Control (full-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (full-dose ranitidine for 3 weeks)
Trial: 2019185
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg qid)
Trial: 2019185
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (40 mg bid)
Trial: 7046974
Drug: IV and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV and oral metoclopramide
Trial: 23530576
Drug: Acarbose 50 mg
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose 50 mg once daily plus isophane protamine biosynthetic human insulin 70/30 injections twice daily 30 min before meals (Group A)
Trial: 23530576
Drug: Acarbose 50 mg
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose 50 mg three times daily plus isophane protamine biosynthetic human insulin 70/30 injections twice daily immediately before meals (Group C)
Trial: 23530576
Drug: Acarbose 50 mg
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose 50 mg three times daily plus isophane protamine biosynthetic human insulin 70/30 injections twice daily 30 min before meals (Group B)
Trial: 21521342
Drug: Hydrocortisone regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone regimen C (10 mg mane/5 mg tarde)
Trial: 21521342
Drug: Hydrocortisone regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone regimen A (20 mg mane/10 mg tarde)
Trial: 21521342
Drug: Hydrocortisone regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone regimen B (10 mg mane/10 mg tarde)
Trial: 21521342
Drug: Hydrocortisone regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone regimen C (10 mg/5 mg)
Trial: 18922087
Drug: Polychromatic visible
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polychromatic visible (pVIS) light exposure (385-750 nm, 95% polarization, 40 mW/cm2, 12 J/cm2) with NOS inhibitor (L-NMMA, 0.1% solution) administered iontophoretically prior to exposure
Trial: 18922087
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with NOS inhibitor (L-NMMA, 0.1% solution) administered to the non-irradiated hand
Trial: 16217756
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation (200 mcg of selenized yeast)
Trial: 12946034
Drug: Aspirin (more
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (more than 325 mg per day)
Trial: 6132935
Drug: Lorazepam (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (1.0 mg)
Trial: 6132935
Drug: Alcohol (1/6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (1/6 or 1/2 gill of vodka, equal to 6.5 or 19.6 g)
Trial: 6132935
Drug: Lorazepam (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (1.0 mg) + Alcohol (1/6 or 1/2 gill of vodka)
Trial: 25218194
Drug: AERAS-402 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AERAS-402 (single dose)
Trial: 15218298
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 i.v. over 1 h followed by gemcitabine 2,000 mg/m2 biweekly until progression or intolerable toxicity
Trial: 1124050
Drug: 2 puffs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 puffs of Sch 1000 administered 6 times
Trial: 23343798
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (100U in 10 mL) via cystoscopy
Trial: 9250256
Drug: Pranlukast 337.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pranlukast 337.5 mg b.i.d.
Trial: 9250256
Drug: Pranlukast 450
RxNorm normalized name: pranlukast
DrugBank: Pranlukast (DB01411)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Pranlukast 450 mg b.i.d.
Trial: 8502270
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (6 g of oil per day, containing 5 g of eicosapentaenoic and docosahexaenoic acid)
Trial: 28710873
Drug: Mecamylamine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mecamylamine 10 mg per day
Trial: 26955311
Drug: Precaine gel
RxNorm normalized name: proparacaine hydrochloride Ophthalmic Solution [Eyecaine]
DrugBank: Cinchocaine (DB00527)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Precaine gel
Trial: 26955311
Drug: Benzocaine topical
RxNorm normalized name: benzocaine topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzocaine topical paste
Trial: 26955311
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no topical anesthetic)
Trial: 8699873
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) infusion (1,200 mg)
Trial: 1969870
Drug: Astemizole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole (10 mg/day)
Trial: 30362375
Drug: Lurbinectedin and
RxNorm normalized name: lurbinectedin
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lurbinectedin and doxorubicin combination
Trial: 30362375
Drug: Standard-of-care chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care chemotherapy (investigator's choice of cyclophosphamide/doxorubicin/vincristine or topotecan)
Trial: 25593135
Drug: Aggressive medical
RxNorm normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive medical management therapy (AMM)
Trial: 25593135
Drug: Percutaneous transluminal
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous transluminal angioplasty and stenting plus aggressive medical therapy (PTAS)
Trial: 19014751
Drug: Olanzapine (5‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5‐20 mg/day)
Trial: 17531327
Drug: Lithium (600‐1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (600‐1800 mg/day)
Trial: 16487090
Drug: Narrow-band ultraviolet
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow-band ultraviolet B (NB-UVB) phototherapy + tacalcitol ointment
Trial: 10861151
Drug: Mechanical stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical stimulation of the larynx (L)
Trial: 10861151
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 4% lidocaine
Trial: 10861151
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine 1 mg/kg
Trial: 9202565
Drug: Intracavernosal self-injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernosal self-injection therapy
Trial: 1528093
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg nalbuphine
Trial: 1528093
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg morphine
Trial: 2859273
Drug: Trimipramine 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimipramine 150 mg/day
Trial: 10807491
Drug: Maprotiline 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maprotiline 150 mg/day
Trial: 21244763
Drug: Oral CsA
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral CsA 5 mg/kg/day for two consecutive days/week for 24 weeks
Trial: 21244763
Drug: Oral CsA
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral CsA 5 mg/kg/day
Trial: 12626887
Drug: 40 mg/d
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/d prednisone as an adjunct to antiretroviral therapy
Trial: 10668714
Drug: Apomorphine 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine 0.05 mg/kg subcutaneously
Trial: 9132322
Drug: Flurbiprofen LAT
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen LAT patches (40 mg, replaced every 12 hours)
Trial: 9132322
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium tablets (50 mg b.d.)
Trial: 8458364
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nifedipine and diltiazem
Trial: 29193016
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg weekly + TCS
Trial: 29193016
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg every 2 weeks + TCS
Trial: 29193016
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (qw + TCS, q2w + TCS, placebo + TCS)
Trial: 22248038
Drug: Flibanserin 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flibanserin 50 mg
Trial: 9112355
Drug: HLA-B2702-derived peptide
RxNorm normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLA-B2702-derived peptide (7 mg/kg)
Trial: 8401617
Drug: OFL: 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OFL: 400 mg per os (n = 95)
Trial: 8401617
Drug: CTRX: 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTRX: 1 g intramuscularly (n = 96)
Trial: 2947710
Drug: Folium Sennae
RxNorm normalized name: Sennae folium
DrugBank: Senna leaf (DB15889)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folium Sennae administered orally
Trial: 2947710
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional medicine; Cimetidine and Rheum officinale)
Trial: 29263227
Drug: Conventional sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional sequential recording
Trial: 27570447
Drug: Evogliptin, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evogliptin, 5 mg od for 7 days (EVO)
Trial: 27570447
Drug: Metformin IR,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin IR, 1,000 mg bid for 7 days (MET)
Trial: 27570447
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of EVO and MET (EVO + MET)
Trial: 17919608
Drug: Oral or
RxNorm normalized name: Doral Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral or vaginal estroprogestative contraception
Trial: 8855809
Drug: LPS (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS (2 ng/kg) + hydrocortisone (3 micrograms/kg.min) for 6 h before LPS injection
Trial: 6841130
Drug: Special dietary
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Special dietary counseling and supplements of Sustagen or Isocal
Trial: 6841130
Drug: No special
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No special advice or supplements (Control)
Trial: 16837885
Drug: Ground flaxseed
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ground flaxseed muffins (25 g, 50 mg lignans)
Trial: 16837885
Drug: Soy flour
RxNorm normalized name: soy flour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy flour muffins (25 g, 42 mg isoflavones)
Trial: 10933649
Drug: Dirithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dirithromycin (500 mg daily for 5 days)
Trial: 8360133
Drug: Clarithromycin 250
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg bd
Trial: 8360133
Drug: Cefaclor 500
RxNorm normalized name: cefaclor 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 500 mg tds
Trial: 3530781
Drug: Bucindolol 100
RxNorm normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bucindolol 100 mg
Trial: 30837554
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive pill (COCP) exposure
Trial: 24249840
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity telemonitoring program (n=40), wore a motion sensor continuously for 18 weeks, received weekly step count goals.